Endocrine Risk Factors for Cognitive Impairment

Jae Hoon Moon

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Cognitive impairment, including Alzheimer’s disease and other kinds of dementia, is a major health problem in older adults worldwide. Although numerous investigators have attempted to develop effective treatment modalities or drugs, there is no reasonably efficacious strategy for preventing or recovering from cognitive impairment. Therefore, modifiable risk factors for cognitive impairment have received attention, and the growing literature of metabolic risk factors for cognitive impairment has expanded from epidemiology to molecular pathogenesis and therapeutic management. This review focuses on the epidemiological evidence for the association between cognitive impairment and several endocrine risk factors, including insulin resistance, dyslipidemia, thyroid dysfunction, vitamin D deficiency, and subclinical atherosclerosis. Researches suggesting possible mechanisms for this association are reviewed. The research investigating modifiable endocrine risk factors for cognitive impairment provides clues for understanding the pathogenesis of cognitive impairment and developing novel treatment modalities. However, so far, interventional studies investigating the beneficial effect of the “modification” of these “modifiable risk factors” on cognitive impairment have reported variable results. Therefore, well-designed, randomized prospective interventional studies are needed.

Keywords: Cognition; Dementia; Risk factors

INTRODUCTION

The prevalence and incidence of cognitive impairment, such as dementia, increases rapidly with advancing age, which results in a huge socioeconomic burden [1]. Dementia is a diagnosis including all kinds of cognitive dysfunction resulting in interference with everyday activities. Alzheimer’s disease, Lewy body dementia, and vascular dementia are types of dementia with various causes and pathogenesis. Dementia is a growing socioeconomic burden that is paralleled by the epidemic increase in its prevalence and incidence. The prevalence of dementia is estimated to be as high as 24 million worldwide and is expected to double every 20 years until 2040 [2]. Medical expenses for people aged 65 years and older with dementia were more than $200 billion in 2013 in the United States [3]. In addition, mild cognitive impairment (MCI), which is a risk for progression to dementia but not sufficient for a diagnosis of dementia, is a common condition in old age: 15% to 42% of people aged ≥65 years are estimated to have MCI, and from about 5% to 15% of them progress to dementia annually [4,5]. Although numerous investigators have attempted to develop effective treatment modalities or drugs, there is no reasonably efficacious strategy for preventing or recovering from cognitive impairment. Only two classes of drugs, cholinesterase inhibitors and memantine, have been approved for the treatment of dementia, and they have shown only modest effects. Therefore,
modifiable risk factors for cognitive impairment have received attention, and the growing literature on metabolic endocrine risk factors for cognitive impairment has expanded from epidemiology and molecular pathogenesis to therapeutic management. This review focuses on the epidemiological evidences of the association between cognitive impairment and several endocrine risk factors, including insulin resistance, dyslipidemia, thyroid dysfunction, vitamin D deficiency, and subclinical atherosclerosis.

**INSULIN RESISTANCE AND COGNITIVE IMPAIRMENT**

The epidemiological association between insulin resistance or type 2 diabetes and cognitive impairment is well established. Several population-based prospective studies and meta-analyses have demonstrated an increased risk of dementia in diabetic patients [6,7]. A recent meta-analysis including 6,184 type 2 diabetes subjects and 38,350 subjects without diabetes pooled from 19 studies reported a combined overall relative risk (RR) of 1.51 (95% confidence interval [CI], 1.31 to 1.74) linking type 2 diabetes with dementia [7]. In particular, the risk of vascular dementia was increased in type 2 diabetes subjects with a RR of 1.46 (95% CI, 2.08 to 2.96) and the risk of Alzheimer’s disease was also increased (RR, 1.46; 95% CI, 1.20 to 1.77) [7]. Diabetes increased not only the risk of MCI, an intermediate stage between normal cognitive function and dementia [8-10], but also the conversion rate to dementia in the subjects with MCI [11,12]. Despite this epidemiological evidence, the mechanisms underlying the association between insulin resistance and cognitive impairment have not been fully understood so far. In people without dementia, type 2 diabetes patients show slightly decreased cognitive function compared with subjects without diabetes in multiple cognitive domains [9,13]. This slight decline in cognitive function of diabetic patients starts from mid-life (about 40 years old) and slowly progresses throughout their lifetime, whereas the incidence of dementia increases sharply after the age of 65 to 70 years [9,14]. Therefore, cognitive decline in type 2 diabetes or insulin resistance and the pathologic process of dementia may be discrete processes, and insulin resistance seems to make the brain more vulnerable to the pathologic process of dementia. A recent review [9] suggested that type 2 diabetes or insulin resistance results in subtle brain atrophy [15], disrupted white matter integrity [16], and vascular abnormalities, including cortical and subcortical infarcts [17,18]. These subtle changes accumulate from mid-life onwards, reducing the reserve capacity of the brain. Some experimental studies have demonstrated direct mechanisms explaining the association between insulin resistance and Alzheimer’s disease. Insulin-degrading enzyme (IDE) breaks down excessive insulin in extracellular milieu and also degrades amyloid β—a key peptide of Alzheimer’s disease pathogenesis, which is derived from the proteolytic cleavage of the amyloid precursor protein and forms the core of senile plaques. Excessive insulin resulting from insulin resistance can compete with amyloid β for the binding site on IDE, resulting in accumulating amyloid β in the central nervous system (CNS) [19]. Interventional studies investigating the effect of diabetes treatment on cognitive function have shown heterogeneous results. The Memory in Diabetes study as part of Action to Control Cardiovascular Risk in Diabetes study (ACCORD-MIND) [20], the largest published randomized controlled study, reported no difference in cognitive decline between type 2 diabetes patients who received intensive glycemic control and those who received conventional glycemic control. A small randomized double-blind trial including 145 subjects demonstrated significant cognitive improvement by add-on therapy of rosiglitazone or glyburide in type 2 diabetes patients receiving metformin monotherapy [21].

**DYSLIPIDEMIA AND COGNITIVE IMPAIRMENT**

The association between hypercholesterolemia and cognitive impairment is still controversial. Several prospective studies demonstrated that hypercholesterolemia in mid-life increased the risk of Alzheimer’s disease and vascular dementia [22-24]. However, a study that followed 1,462 women over 32 years failed to demonstrate any association between midlife hypercholesterolemia and the risk of Alzheimer’s disease, and some studies reported the protective effect of hypercholesterolemia in late life against Alzheimer’s disease [25-27]. Although vigorous treatment of hypercholesterolemia has been thought to decrease the risk of vascular dementia considering the benefits of statins in the primary and secondary prevention of stroke, the beneficial effect of statin therapy on cognitive impairment has not been firmly established. Based on isolated case reports without established causality, there has been concern that statins may actually worsen cognitive function and memory [28,29]. A prospective study evaluating 1,674 participants without dementia showed that statin therapy decreased the risk of dementia during the 5-year follow-up period after adjust-
ment for conventional risk factors for dementia [30]. Other cross-sectional and prospective studies also reported the beneficial effect of statin therapy on cognitive impairment [31-33]. Experimental studies have suggested that the cholesterol distribution in neuronal cell membrane was associated with amyloid \( \beta \) synthesis and metabolism [27]. Proteins required for cholesterol recycling and trafficking, such as apolipoprotein E, low density lipoprotein (LDL) receptor, and low density lipoprotein receptor-related protein 1 (LRP1), also play a role in amyloid \( \beta \) homeostasis in the brain [34-36]. In addition, LDL receptor and LRP1 have been reported to be regulated by statin drugs [37]. Altogether, lipid metabolism might be associated with the pathogenesis of Alzheimer’s disease and vascular dementia, and some experimental and clinical studies have provided some evidence for this association. However, further studies, including well-designed interventional studies, are needed to confirm the association between dyslipidemia and cognitive impairment.

**THYROID HORMONE AND COGNITIVE IMPAIRMENT**

Thyroid hormone is an important neuroregulator in fetal development of the CNS and plays an important role in neurocognitive function after development. Overt hypothyroidism is a well-known reversible factor causing cognitive impairment including dementia [38]. Overt hyperthyroidism or thyrotoxicosis has also been known to be associated with altered concentration and perception [39]. Epidemiologically, thyroid dysfunction, depression, and cognitive impairment commonly increase in older adults and recent studies have reported that thyroid dysfunction is one of the risk factors for irreversible cognitive impairment, such as Alzheimer’s disease [40]. On the basis of this association between thyroid dysfunction and psychiatric disorders, a number of investigators have sought to determine whether subclinical thyroid dysfunction is a risk factor for cognitive impairment, especially in older adults. Although the effect of subclinical hypothyroidism on cognitive impairment is still questionable [40,41], the association between subclinical hyperthyroidism and cognitive impairment has been validated in several studies [39,42-44]. In the Rotterdam study [42] that followed up 1,843 non-demented participants for 2 years, subjects with thyroid stimulating hormone (TSH) levels below 0.4 mIU/L at baseline had a greater than 3-fold increased risk of dementia (RR, 3.5; 95% CI, 1.2 to 10.0) and Alzheimer’s disease (RR, 3.5; 95% CI, 1.1 to 11.5) after adjusting for age and sex compared with those at the euthyroid level. In the Thyroid Epidemiology, Audit, and Research Study [44], a large observational study including 12,115 euthyroid and subclinical hyperthyroid subjects with a median follow-up period of 5.6 years, participants with serum TSH levels below 0.4 mIU/L at baseline had a 2-fold increased risk of dementia. Moreover, a few cross-sectional studies suggested that even a normal serum TSH level, when ranging in the lower reference level, might be associated with the risk of dementia [45,46]. A recent community-based prospective cohort study demonstrated that lower serum TSH concentration within the reference range was associated with the development or progression of cognitive impairment including MCI and dementia in older adults [47]. MCI or dementia developed in 12.5% of 200 subjects with baseline TSH of more than 1.82 mIU/L, whereas MCI or dementia developed in 25.7% of 113 subjects with baseline TSH of less than 1.82 mIU/L [47]. However, there was no difference in the cognitive function between elderly patients with differentiated thyroid carcinoma who received long-term TSH suppressive therapy (iatrogenic subclinical thyrotoxicosis) and euthyroid control subjects; moreover, there were positive correlations between serum free thyroxine (T4) levels and some cognitive domains [48].

The mechanism underlying the association between low TSH and the risk of cognitive decline is still unclear. Of the two widely accepted explanations, the first and most conventional explanation is the toxic effect of excessive thyroid hormone on the CNS [39]. Brain oxidative stress caused by an excess of thyroid hormone or thromboembolism from the cardiac effects of mild hyperthyroidism have been suggested as underlying mechanisms [39,49]. Second, neurodegenerative changes in the brain, which may cause a cognitive decline, can also result in a reduced secretion of thyrotropin releasing hormone (TRH) in the brain and, in turn, reduce the secretion of TSH [39]. TRH is secreted not only from the hypothalamus but also from other areas of the brain, and is known to play a role as a CNS neurotransmitter, suggesting that TRH secretion may decrease in the brain of subjects with cognitive impairment [39,50]. As mentioned above, long-term iatrogenic subclinical thyrotoxicosis or a mild excess of thyroid hormone did not result in a cognitive decline in elderly subjects [48]. This finding suggests that reduced TRH in the degenerated brain is the most reliable explanation. Furthermore, the positive correlations between serum free T4 levels and some cognitive domains suggest the potential beneficial effect of exogenous levothyroxine on cognitive function.
VITAMIN D DEFICIENCY AND COGNITIVE IMPAIRMENT

Vitamin D status is determined by the serum level of 25-hydroxyvitamin D, or 25(OH)D, and a low vitamin D status is common and considered a major health problem in elderly populations [51-53]. Several studies have reported that low vitamin D status is associated with poor bone health and other conditions including cardiovascular disease (CVD), insulin resistance, autoimmune diseases and certain malignancies [54-56]. Low vitamin D status has also received attention as a potential metabolic risk factor for dementia. A number of studies have shown that a low serum 25(OH)D concentration is associated with an increased risk of dementia and Alzheimer’s disease in older adults [57,58]. A recent community-based prospective study of the elderly demonstrated that low vitamin D status increased the risk of MCI as well as dementia [59]. They reported that the RR of MCI development during a 5-year follow-up was 7.13 (95% CI, 1.54 to 32.92; \( P=0.012 \)) in the elderly subjects whose serum 25(OH)D concentration was <25.0 nmol/L compared with those with a serum 25(OH)D concentration \( \geq 50.0 \) nmol/L [59]. Several studies have suggested that long-term hypovitaminosis D status results in CNS inflammation and Aβ accumulation via oxidative stress, alteration in CNS cytokine levels, neurotransmitter dysregulation, and macrophage dysfunction [60]. However, it is still unclear whether vitamin D replacement therapy can prevent or aid recovery from cognitive impairment, and well-designed interventional studies are needed.

SUBCLINICAL ATHEROSCLEROSIS AND COGNITIVE IMPAIRMENT

Recent large-scale prospective cohort studies have demonstrated that CVD risk factors, including 10-year CVD risk scores and individual CVD risk factors, are associated with cognitive decline [61-68]. A longitudinal British cohort study (Whitehall-II) including 5,810 participants showed that elevated stroke risk as measured by the Framingham stroke risk (FSR) score in mid-life is associated with accelerated cognitive decline over 10 years [67]. The English Longitudinal Study of Aging including 8,780 subjects also reported the association between high FSR score and cognitive decline over 4 years [66]. FSR score was also associated with the 4-year cognitive decline in 1,907 stroke-free subjects [65]. The sex-specific 10-year CVD risk score was reported to be associated with the 10-year cognitive decline in 1,116 aged Mexican Americans [68]. Other individual CVD risk factors including hypertension, dyslipidemia, obesity, and diabetes in mid-life have been suggested as risk factors for cognitive decline and dementia in later life [61-64]. Surrogate markers for CVD risk, including carotid intimal-media thickness (CIMT) and pulse wave velocity (PWV) have been reported to be associated with cognitive impairment in a number of studies [69-76]. A recent prospective cohort study investigated the association between CVD risk factors, including CIMT, PWV, ankle-brachial index and other biochemical and anthropometric markers, and the future risk of clinically diagnosed MCI or dementia [77]. They demonstrated that CIMT was the best predictor of the development of MCI and dementia over 5 years and the hazard ratio for the development of MCI and dementia per 0.1 mm increase in CIMT was about 1.25 [77].

At present, it remains unclear whether a vascular pathology such as increased CIMT can cause cognitive decline in elderly subjects or whether it simply develops as an early vascular response associated with neuronal degeneration. Recent studies have shown that vascular dysfunction is involved in the pathogenesis of not only vascular dementia but also Alzheimer’s disease [78]. Vascular dysfunction results in the restriction of oxygen and glucose supply to the brain, and Aβ accumulation in the brain affects vascular pathology and exacerbates blood flow restriction to the brain [78-80]. In addition, vascular dysfunction can cause reduced Aβ clearance across the blood-brain barrier, and oxidative stress is also a common pathogenic mechanism between vascular dysfunction and Alzheimer’s disease [78]. Therefore, vascular dysfunction and Aβ deposition might have synergistic effects on neuronal degeneration [78].

CONCLUSIONS

The effort to discover modifiable risk factors for cognitive impairment has identified important endocrine risk factors for cognitive impairment. Epidemiological studies have reported associations between metabolic risk factors and cognitive impairment, and experimental studies have suggested mechanisms that can explain these associations. This effort is important for providing a theoretical basis of novel treatment modalities for cognitive impairment. However, so far, interventional studies to investigate the beneficial effect of the “modification” of these “modifiable risk factors” on cognitive impairment have reported variable results. Therefore, future well-designed randomized controlled trials are needed.
CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Jae Hoon Moon  http://orcid.org/0000-0001-6327-0575

REFERENCES

1. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Cope\-land JR, Dartigues JF, et al. Incidence of dementia and ma\-jor subtypes in Europe: a collaborative study of population\-based cohorts. Neurologic Diseases in the Elderly Research \ Group. Neurology 2000;54(11 Suppl 5):S10-5.
2. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer \ disease. Nat Rev Neurol 2011;7:137-52.
3. Alzheimer’s Association. 2013 Alzheimer’s disease facts \ and figures. Alzheimers Dement 2013;9:208-45.
4. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, \ Wahlund LO, et al. Mild cognitive impairment: beyond con\-troversies, towards a consensus: report of the International \ Working Group on Mild Cognitive Impairment. J Intern Med \ 2004;256:240-6.
5. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evo\lution. J Intern Med 2014;275:214-28.
6. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic re\-view. Lancet Neurol 2006;5:64-74.
7. Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk fac\tor for dementia and mild cognitive impairment: a meta\-analysis of longitudinal studies. Intern Med J 2012;42:484-91.
8. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, May\-eux R. Relation of diabetes to mild cognitive impairment. Arch \ Neurol 2007;64:570-5.
9. Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whit\-mer RA. Dementia and cognitive decline in type 2 diabetes \ and prediabetic stages: towards targeted interventions. Lance\t Diabetes Endocrinol 2014;2:246-55.
10. Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz \ VS, Baertlein L, et al. Association of diabetes with amnestic \ and nonamnestic mild cognitive impairment. Alzheimers Dement \ 2014;10:18-26.
MR, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: a population-based study of African Americans. Neurology 2000;54:240-2.

23. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Halikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001;322:1447-51.

24. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009;28:75-80.

25. Mielke MM, Zandi PP, Shao H, Waern M, Ostling S, Guo X, et al. The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology 2010;75:1888-95.

26. Cedazo-Minguez A, Ismail MA, Mateos L. Plasma cholesterol and risk for late-onset Alzheimer’s disease. Expert Rev Neurother 2011;11:495-8.

27. Chakrabarti S, Khemka VK, Banerjee A, Chatterjee G, Ganguly A, Biswas A. Metabolic risk factors of sporadic Alzheimer’s disease: implications in the pathology, pathogenesis and treatment. Aging Dis 2015;6:282-99.

28. Wagstaff LR, Mitton MW, Arvik BM, Doraismwamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-80.

29. Menezes AR, Lavie CJ, Milani RV, O’Keefe J. The effects of statins on prevention of stroke and dementia: a review. J Cardiopulm Rehabil Prev 2012;32:240-9.

30. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008;71:344-50.

31. Santanello NC, Barber BL, Applegate WB, Elam J, Curtis C, Hunninghake DB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 1997;45:8-14.

32. Wolozin B, Kellman W, Russoeau P, Celasia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.

33. Muangpaisan W, Brayne C; Alzheimer’s Society Vascular Dementia Systematic Review Group. Systematic review of statins for the prevention of vascular dementia or dementia. Geriatr Gerontol Int 2010;10:199-208.

34. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-99.

35. Goto JJ, Tanzi RE. The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer’s A beta generation: development of a cell-based model system. J Mol Neurosci 2002;19:37-41.

36. Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid beta-peptide elimination from the brain. J Neurochem 2010;115:1077-89.

37. Moon JH, Kang SB, Park JS, Lee BW, Kang ES, Ahn CW, et al. Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression. Metabolism 2011;60:930-40.

38. Davis JD, Tremont G. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva Endocrinol 2007;32:49-65.

39. Gan EH, Pearce SH. Clinical review: the thyroid in mind: cognitive function and low thyrotropin in older people. J Clin Endocrinol Metab 2012;97:3438-49.

40. Tan ZS, Vasan RS. Thyroid function and Alzheimer’s disease. J Alzheimers Dis 2009;16:503-7.

41. Samuels MH. Cognitive function in subclinical hypothyroidism. J Clin Endocrinol Metab 2010;95:3611-3.

42. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf) 2000;53:733-7.

43. Tan ZS, Beiser A, Vasan RS, Au R, Auerbach S, Kiel DP, et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med 2008;168:1514-20.

44. Vadieloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011;96:1344-51.

45. Dobert N, Hamscho N, Menzel C, Peters J, Frolich L, Tsolakis A, et al. Subclinical hyperthyroidism in dementia and correlation of the metabolic index in FDG-PET. Acta Med Austriaca 2003;30:130-3.

46. van Osch LA, Hogervorst E, Combrinck M, Smith AD. Low
thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology 2004;62:1967-71.
47. Moon JH, Park YJ, Kim TH, Han JW, Choi SH, Lim S, et al. Lower-but-normal serum TSH level is associated with the development or progression of cognitive impairment in elderly: Korean Longitudinal Study on Health and Aging (KLoSHA). J Clin Endocrinol Metab 2014;99:424-32.
48. Moon JH, Ahn S, Seo J, Han JW, Kim KM, Choi SH, et al. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2014;99:3782-9.
49. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008;29:76-131.
50. Brownstein MJ, Palkovits M, Saavedra JM, Bassiri RM, Utiger RD. Thyrotropin-releasing hormone in specific nuclei of rat brain. Science 1974;185:267-9.
51. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
52. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. BMJ 2010;340:b5664.
53. Formiga F, Ferrer A, Almeda J, San Jose A, Gil A, Pujol R. Utility of geriatric assessment tools to identify 85-years old subjects with vitamin D deficiency. J Nutr Health Aging 2011;15:110-4.
54. Perez-Lopez FR, Chedraui P, Fernandez-Alonso AM. Vitamin D and aging: beyond calcium and bone metabolism. Maturitas 2011;69:27-36.
55. Holick MF. Vitamin D: a D-lightful vitamin for health. Endocrinol Metab 2012;27:255-67.
56. Lim S, Shin H, Kim MJ, Ahn HY, Kang SM, Yoon JW, et al. Vitamin D inadequacy is associated with significant coronary artery stenosis in a community-based elderly cohort: the Korean Longitudinal Study on Health and Aging. J Clin Endocrinol Metab 2012;97:169-78.
57. Balion C, Griffith LE, Strifler L, Henderson M, Patterson C, Heckman G, et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology 2012;79:1397-405.
58. Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology 2014;83:920-8.
59. Moon JH, Lim S, Han JW, Kim KM, Choi SH, Kim KW, et al. Serum 25-hydroxyvitamin D level and the risk of mild cognitive impairment and dementia: the Korean Longitudinal Study on Health and Aging (KLoSHA). Clin Endocrinol (Oxf) 2015;83:36-42.
60. Gezen-Ak D, Yilmazer S, Dursun E. Why vitamin D in Alzheimer’s disease? The hypothesis. J Alzheimers Dis 2014;40:257-69.
61. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-Year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5.
62. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003;163:1524-8.
63. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61:661-6.
64. Kivipelto M, Ngandu T, Laattikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006;5:735-41.
65. Unverzagt FW, McClure LA, Wadley VG, Jenny NS, Go RC, Cushman M, et al. Vascular risk factors and cognitive impairment in a stroke-free cohort. Neurology 2011;77:1729-36.
66. Dregan A, Stewart R, Gulliford MC. Cardiovascular risk factors and cognitive decline in adults aged 50 and over: a population-based cohort study. Age Ageing 2013;42:338-45.
67. Kaffashian S, Dugravot A, Brunner EJ, Sabia S, Ankri J, Kivimaki M, et al. Midlife stroke risk and cognitive decline: a 10-year follow-up of the Whitehall II cohort study. Alzheimers Dement 2013;9:572-9.
68. Zeki Al Hazzouri A, Haan MN, Neuhaus JM, Pletcher M, Peralta CA, Lopez L, et al. Cardiovascular risk score, cognitive decline, and dementia in older Mexican Americans: the role of sex and education. J Am Heart Assoc 2013;2:e004978.
69. Komulainen P, Kivipelto M, Lakka TA, Hassinen M, Helkala EL, Patja K, et al. Carotid intima-media thickness and cognitive function in elderly women: a population-based study. Neuroepidemiology 2007;28:207-13.
70. Dregan A, Stewart R, Gulliford MC. Cardiovascular risk factors and cognitive decline in adults aged 50 and over: a population-based cohort study. Age Ageing 2013;42:338-45.
71. Kaffashian S, Dugravot A, Brunner EJ, Sabia S, Ankri J, Kivimaki M, et al. Midlife stroke risk and cognitive decline: a 10-year follow-up of the Whitehall II cohort study. Alzheimers Dement 2013;9:572-9.
72. Zeki Al Hazzouri A, Haan MN, Neuhaus JM, Pletcher M, Peralta CA, Lopez L, et al. Cardiovascular risk score, cognitive decline, and dementia in older Mexican Americans: the role of sex and education. J Am Heart Assoc 2013;2:e004978.
73. Komulainen P, Kivipelto M, Lakka TA, Hassinen M, Helkala EL, Patja K, et al. Carotid intima-media thickness and cognitive function in elderly women: a population-based study. Neuroepidemiology 2007;28:207-13.
74. Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 2009;40:3180-5.
75. Sander K, Bickel H, Forstl H, Etgen T, Briesenick C, Poppert H, et al. Carotid- intima media thickness is independently associated with cognitive decline. The INVAGE study. Int J Geriatr Psychiatry 2010;25:389-94.
73. Arntzen KA, Schirmer H, Johnsen SH, Wilsgaard T, Mathiesen EB. Carotid artery plaque progression and cognitive decline: the Tromso Study 1994-2008. Eur J Neurol 2012; 19:1318-24.

74. Zhong W, Cruickshanks KJ, Schubert CR, Acher CW, Carlson CM, Klein BE, et al. Carotid atherosclerosis and 10-year changes in cognitive function. Atherosclerosis 2012; 224:506-10.

75. Zeki Al Hazzouri A, Newman AB, Simonsick E, Sink KM, Sutton Tyrrell K, Watson N, et al. Pulse wave velocity and cognitive decline in elders: the Health, Aging, and Body Composition study. Stroke 2013;44:388-93.

76. Masley SC, Masley LV, Gualtieri CT. Cardiovascular biomarkers and carotid IMT scores as predictors of cognitive function. J Am Coll Nutr 2014;33:63-9.

77. Moon JH, Lim S, Han JW, Kim KM, Choi SH, Park KS, et al. Carotid intima-media thickness is associated with the progression of cognitive impairment in older adults. Stroke 2015;46:1024-30.

78. Murray IV, Proza JF, Sohrabji F, Lawler JM. Vascular and metabolic dysfunction in Alzheimer’s disease: a review. Exp Biol Med (Maywood) 2011;236:772-82.

79. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004;3:169-78.

80. Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol (1985) 2006;100:328-35.